Show simple item record

dc.contributor.authorGungorduk, Kemal
dc.contributor.authorPlett, Helmut
dc.contributor.authorGulseren, Varol
dc.contributor.authorMeydanli, Mutlu
dc.contributor.authorBoyraz, Gokhan
dc.contributor.authorOzdemir, IsaAykut
dc.contributor.authorSahin, Hanifi
dc.contributor.authorSenol, Taylan
dc.contributor.authorYildirim, Nuri
dc.contributor.authorTuran, Taner
dc.contributor.authorOge, Tayfun
dc.contributor.authorGokcu, Mehmet
dc.contributor.authorTaskin, Salih
dc.contributor.authorAyhan, Ali
dc.contributor.authorAtaseven, Beyhan
dc.date.accessioned2020-12-31T09:13:21Z
dc.date.available2020-12-31T09:13:21Z
dc.date.issued2020
dc.identifier.issn2296-5270en_US
dc.identifier.urihttp://hdl.handle.net/11727/5324
dc.description.abstractAim: The clinicopathologic characteristics, recurrence patterns, and survival of patients with grade 3 endometrial cancer (G3-EAC) and uterine carcinosarcoma (UCS) were compared. Materials and Methods: The medical records of patients treated for G3-EAC and UCS between January 1996 and December 2016 at 11 gynecologic oncology centers in Turkey and Germany were analyzed. Results: Of all patients included in the study, 161 (45.1%) were diagnosed with UCS and 196 (54.9%) with G3-EAC at FIGO stage I-II (early stage) disease. The recurrence rate was higher in patients with UCS than in those with G3-EAC (17.4 vs. 9.2%, p = 0.02). The 5-year disease-free survival (DFS; 75.2 and 80.8%, respectively; p = 0.03) and overall survival (OS; 79.4 and 83.4%, respectively; p = 0.04) rates were significantly lower in the UCS group compared to the G3-EAC group. UCS histology was an independent prognostic factor for decreased 5-year DFS (HR 1.8, 95% CI 1.2-3.2; p = 0.034) and OS (HR 2.7, 95% CI 1.3-6.9; p = 0.041) rates. Conclusions: The recurrence rate was higher in UCS patients than in G3-EAC patients, regardless of disease stage. DFS and OS were of shorter duration in UCS than in G3-EAC patients. Adequate systematic lymphadenectomy and omentectomy were an independent prognostic factor for increased 5-year DFS and OS rates.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1159/000511288en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometrial canceren_US
dc.subjectGrade 3 endometrial canceren_US
dc.subjectUterine carcinosarcomaen_US
dc.subjectRecurrenceen_US
dc.titleIs the Oncological Outcome of Early Stage Uterine Carcinosarcoma Different from That of Grade 3 Endometrioid Adenocarcinoma?en_US
dc.typearticleen_US
dc.relation.journalONCOLOGY RESEARCH AND TREATMENTen_US
dc.identifier.wos000595977500001en_US
dc.contributor.pubmedID33249415en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record